Assessment of the efficacy of a peroral anticoagulant after surgical resection of gastric cancer
Автор: Katelnitskaya Oksana V., Kit Oleg I., Katelnitsky Igor I., Duritsky Maksim N., Guskova Nailya K., Gabrichidze Petr N., Zakharchenko Viktoria R., Snezhko Aleksandr V., Przhedetskiy Yuriy А., Poluektov Sergey I., Pustovalova Alla V.
Журнал: Cardiometry @cardiometry
Рубрика: Original research
Статья в выпуске: 13, 2018 года.
Бесплатный доступ
Aims Patients suffering from gastric cancer have a high risk of postoperative thrombotic complications and often use anticoagulants. Direct oral anticoagulants absorb in the proximal region of the digestive tract. Consequently, a reduction in anticoagulating activity is possible. In the present research given is an evaluation of the anti-Xa activity upon administration of Rivaroxaban at a fixed dose of 20 mg once daily in oncological patients after gastrectomy or cases of extensive resection of the stomach. Materials and methods The study cohort covered 20 patients after surgical treatment of gastric cancer having normal renal/hepatic function. The patients received Rivaroxaban at a fixed dose of 20 mg once daily to prevent venous thromboembolic complications.
Gastrectomy, anti-xa activity, rivaroxaban, vein thrombosis
Короткий адрес: https://sciup.org/148308853
IDR: 148308853 | DOI: 10.12710/cardiometry.2018.13.5457
Список литературы Assessment of the efficacy of a peroral anticoagulant after surgical resection of gastric cancer
- Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann. Surg. 2006;243 (1):89-95.
- Russian Society of Clinical Onkology. http://www. oncology.ru/russco/
- Schulman S, Zondag M, Linkins L, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis, J. Thromb. Haemost. 2015 Jun 13;1010-8
- Chee CE, Ashrani AA, Marks RS, et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood. 2014;123(25):3972-8.
- Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers, Arch. Int. Med. Am. Med. Assoc. 2006 Feb 27;166:458-64
- Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost. 2007;5:632-4.
- Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb. J. 20 Sep 2013;11:1.
- Mueck W, Stampfuss J, Kubitza D, et al. Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban. Clin Pharmacokinet. 2014;53:1-16. DOI 10.1007/s40262-013-0100-7
- Rathbun A, Tafur R, Grant N, et al. Comparison of Methods to Determine Rivaroxaban anti-factor Xa activity. Thrombosis Research. 2018; 164:S168-S171. 10. Samama MM, Contant G, Spiro TE, et al. Laboratory assessment of rivaroxaban: a review. Thrombosis Journal. 2013;11:11.
- Beyer J, Trujillo T, Fisher S, et al. Evaluation of aheparin-calibrated Antifactor Xa assay for measuring the anticoagulant effect of oral direct Xa inhibitors. Clin. Appl. Thromb. Hemost. 2016;22:423-8
- Sakaguchi T, et al. Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban. Journal of Cardiology. 2017;70:244-9
- Cheung YW, Barco S, Mathôt RAA, van den Dool E, et al. Coppens Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. Thrombosis Research. 2017;160:76-82.
